Search research articles
Contact Us
Filters
Showing results (21-30 of 60) with videos related to
Page
of 6
Sort By:
ESMO Open
|
June 18, 2025
Outcomes with trastuzumab deruxtecan by biomarker status, line of treatment and prior receipt of sacituzumab govitecan in a large real-world database of patients with metastatic breast cancer
P Tarantino, D Lee, J Foldi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 1, 2020
A Food and Drug Administration analysis of survival outcomes comparing the Adjuvant Paclitaxel and Trastuzumab trial with an external control from historical clinical trials
L Amiri-Kordestani, D Xie, S M Tolaney, et al.
ESMO Open
|
March 5, 2026
Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in ER-positive, HER2-negative advanced breast cancer: an indirect treatment comparison of three phase III trials
K Jhaveri, F C Bidard, K Kalinsky, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 23, 2021
Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?
P Tarantino, H J Burstein, N U Lin, et al.
ESMO Open
|
June 4, 2024
Phase Ib dose-escalation trial of taselisib (GDC-0032) in combination with HER2-directed therapies in patients with advanced HER2+ breast cancer
A Grinshpun, S Ren, N Graham, et al.
Cancer Immunology, Immunotherapy : CII
|
February 24, 2023
Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial
A S Feils, A K Erbe, J Birstler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 30, 2026
Metastatic breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up<sup>†</sup>
E de Azambuja, C H Barrios, R Bartsch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 29, 2020
Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases
O Metzger Filho, J P Leone, T Li, et al.
ESMO Open
|
February 11, 2026
Circulating tumor DNA in neoadjuvant endocrine therapy for early breast cancer
A Grinshpun, D Dustin, M Cai, et al.
ESMO Open
|
June 4, 2025
Clinicopathological features and genomics of ER-positive/HER2-negative breast cancer relapsing on adjuvant abemaciclib
C Corti, A R Martin, P T Kurnia, et al.
Page
of 6
Search research articles
Search
Showing results (21-30 of 60) with videos related to
Sort By:
Page
of 6
ESMO Open
|
June 18, 2025
Outcomes with trastuzumab deruxtecan by biomarker status, line of treatment and prior receipt of sacituzumab govitecan in a large real-world database of patients with metastatic breast cancer
P Tarantino, D Lee, J Foldi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 1, 2020
A Food and Drug Administration analysis of survival outcomes comparing the Adjuvant Paclitaxel and Trastuzumab trial with an external control from historical clinical trials
L Amiri-Kordestani, D Xie, S M Tolaney, et al.
ESMO Open
|
March 5, 2026
Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in ER-positive, HER2-negative advanced breast cancer: an indirect treatment comparison of three phase III trials
K Jhaveri, F C Bidard, K Kalinsky, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 23, 2021
Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?
P Tarantino, H J Burstein, N U Lin, et al.
ESMO Open
|
June 4, 2024
Phase Ib dose-escalation trial of taselisib (GDC-0032) in combination with HER2-directed therapies in patients with advanced HER2+ breast cancer
A Grinshpun, S Ren, N Graham, et al.
Cancer Immunology, Immunotherapy : CII
|
February 24, 2023
Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial
A S Feils, A K Erbe, J Birstler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 30, 2026
Metastatic breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up<sup>†</sup>
E de Azambuja, C H Barrios, R Bartsch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 29, 2020
Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases
O Metzger Filho, J P Leone, T Li, et al.
ESMO Open
|
February 11, 2026
Circulating tumor DNA in neoadjuvant endocrine therapy for early breast cancer
A Grinshpun, D Dustin, M Cai, et al.
ESMO Open
|
June 4, 2025
Clinicopathological features and genomics of ER-positive/HER2-negative breast cancer relapsing on adjuvant abemaciclib
C Corti, A R Martin, P T Kurnia, et al.
Page
of 6